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Abstract 
Hepatic stellate cells (HSCs), also known as perisinusoidal cells, are pericytes found 
in the perisinusoidal space of the liver. HSCs are the major cell type involved in liver 
fibrosis, which is the formation of scar tissue in response to liver damage. When the 
liver is damaged, stellate cells can shift into an activated state, characterized by 
proliferation, contractility, and chemotaxis. The activated HSCs secrete collagen scar 
tissue, which can lead to cirrhosis. Recent studies have also shown that in vivo 
activation of HSCs by fibrogenic agents can eventually lead to senescence of these 
cells, which may limit fibrosis but may also favor the insurgence of liver cancer. 
Retinoic acid is a metabolite of vitamin A (retinol) that mediates the functions of vitamin 
A required for growth and development. HSCs store vitamin A, which decreases 
progressively in liver injury. Retinoic acid and its receptors (RAR and RXR) are known 
to act synergistically with peroxisome proliferator-activated receptor gamma (PPAR-
gamma) signaling in various cell types, through the activity of transcriptional 
heterodimers. Here we review the recent advancements in the understanding of how 
retinoic acid signaling modulates the fibrogenic potential of HSCs. 
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Introduction  
Hepatic stellate cells (HSCs), also known as perisinusoidal cells, Ito cells or lipocytes, 
are non-parenchymal cells located in the space between the endothelial cells of 
sinusoids and the hepatocytes, representing approximately the 5-8% of resident liver 
cells. As suggested by their name, HSCs show a star-like shape with the cell body 
lying between the parenchymal cells of the liver and a number of cytoplasmic 
processes embracing sinusoids and making contact with hepatocytes and other HSCs’ 
processes [1, 2]. In the healthy liver, HSCs are found in a quiescent state and exhibit 
lipid droplets storing large amounts of retinoids, mainly in the form of retinyl esters [3, 
4]. Apart from the regulation of retinol homeostasis, the functions of these cells in the 
healthy adult liver are yet not fully understood. In recent years, new roles for HSCs in 
liver development during embryogenesis [1, 5] and in immunity, as antigen-presenting 
cells [3, 6, 7] have been proposed. Well known  instead is the pivotal role HSCs play 
in  response to liver injury, upon which they transdifferentiate into activated cells. 
Activated HSCs acquire a myofibroblast-like morphology, lose their retinol stores, 
become proliferative and contractile, migrate to the site of injury and begin to produce 
extracellular matrix to protect against further damage, and cytokines and growth 
factors which favor the regeneration and replacement of damaged hepatocytes [5]. 
Chronic activation of HSCs following persistent liver damage (either due to viral 
hepatitis viruses, alcohol, toxins, or autoimmune disorders) results in promotion of 
fibrosis, because of the deposition of excessive amounts of scar tissue, which alters 
the structure and functionality of the liver [5]. Liver fibrosis often represents the starting 
setting for the development of cirrhosis, which finally may evolve into hepatocellular 
carcinoma (HCC). 
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Hepatic stellate cells and senescence 
The activation of the HSCs occurring upon liver injury and leading to fibrosis is 
somehow a self-limiting process. Indeed, besides proliferating, HSCs performing 
extracellular matrix deposition, also apoptotic and senescent HSCs can be found in 
fibrotic liver, and this would account for fibrosis reversal [8-10].  
Cellular senescence (also called replicative senescence) is a phenomenon in which 
mitotic cells permanently stop dividing yet remaining metabolically active. Several 
events have been described as promoters of senescence, among which are telomere 
shortening after a number of replicative cycles, DNA damage, alteration of chromatin 
structure, oncogene activation or tumor-suppressor gene loss, oxidative stress and 
other kinds of stress [11, 12]. Typical features that mark senescent cells are 
irreversible cell cycle arrest sustained by p53 and p16/Rb pathways, morphological 
changes (above all increased cell size and flattened morphology), expression of 
senescence-associated β-galactosidase(SA-βgal), expression of a senescence-
associated secretory phenotype  (SASP) consisting in the production of cytokines, 
chemokines, growth factors, proteases and other bioactive molecules acting in a 
autocrine and paracrine fashion [11, 13]. 
Interleukin-22 (IL-22) has been recognized as a stimulus triggering senescence in 
HSCs [14].IL-22 is a cytokine produced by T lymphocytes and Natural Killer (NK) cells 
and reported to target epithelial cells of the skin, kidney, digestive and respiratory 
systems and hepatocytes [15]. It acts by binding a heterodimeric receptor composed 
by IL-10R2 and IL-22R1, then activating the JAK/STAT and MAP kinases pathways 
and resulting in mediation of immune responses, tissue protection from injury and 
regeneration [15]. 
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Interestingly, cultured murine and human HSCs were recently found to express the IL-
10R2 and IL-22R1 receptors, and when treated with IL-22, underwent senescence 
[14]. Consistently, in transgenic mice overexpressing IL-22 the degree of liver fibrosis 
was reduced and the resolution of fibrosis was faster than in wild- type mice. This pro-
senescence phenotype triggered by IL-22 occurs via the activation of the STAT3 and 
the SOCS3 pathways, as already shown in hepatocytes [16], by increasing the 
phosphorylation levels of these effectors either in primary mouse and human HSCs 
and in the human LX2 HSC cell line [14]. Moreover, HSCs lacking STAT3 or SOCS3 
fail to induce p53 and p21, which are likely responsible for the cell cycle block occurring 
during senescence [14]. 
Another inducer of senescence in HSCs is represented by CCN1 (also known as 
CYR61 or cystein-rich 61) [17], a non-structural protein of the extracellular matrix 
whose expression is induced upon injury [17, 18]. Mice lacking hepatic CCN1 treated 
with the hepatotoxic compound carbon tetrachloride (CCl4), exhibit a more pronounced 
liver fibrosis and a decreased number of senescent cells, as judged on the basis of 
the expression of the SA-β-Gal marker, when compared to control mice [17]. 
Moreover, purified CCN1 administered to isolated activated HSCs pushes them into 
senescence by binding to α1β1 integrin, inducing the Rac1/Nox1 pathway, and 
resulting in accumulation of reactive oxygen species (ROS) [17], which are known 
mediators of senescence [19].  
On the other hand, the commitment of HSCs towards senescence is counteracted by 
adenosine, a molecule rapidly produced in response to cell injury [8]. Binding of 
adenosine to its A2A receptor on HSCs has a pro-fibrotic effect since it stimulates 
collagen production [20]. Ahsan et al. demonstrated that by binding to the A2A receptor 
on both LX2 cell line and primary rat HSCs, adenosine activates the 
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PKA/Rac1/p38MAPK pathway and this results in suppression of p53 and Rb, two 
proteins required for senescence initiation [8].  
Based on the mechanisms described above, it is clear that once activated the fate of 
HSCs (proliferation, apoptosis or senescence) depends on an ill-known balance 
between pro- and anti-fibrotic endogenous molecules acting locally. 
This feature is taking a centre stage since the secretory pattern of senescent cells can 
create an inflammatory environment favoring HCC. Although long considered a 
mechanism to prevent proliferation of mutated cells, it is now clear that senescence 
may also play the opposite role, triggering tumor development and progression [13, 
21, 22]. Indeed, among the factors secreted by senescent cells there are growth 
factors which can induce cell proliferation, chemokines and metalloproteases which 
can promote cell migration and invasion [21]. 
A strong link between HSCs senescence and HCC development has been described 
in mouse models of obesity [22]. Obesity is a well-known risk factor for cancer, 
including  HCC, but the underlying mechanisms are poorly understood. Yoshimoto et 
al. showed that changes in the intestinal microbiota play a key role in HCC 
development in both genetically obese and high-fat diet fed mice. In these models, an 
increase in Gram-positive gut bacteria, especially those belonging to the Clostridium 
clusters XI and XIVa, resulted in increased production of the metabolite deoxycholic 
acid (DCA). On reaching  the liver through the enterohepatic circulation, DCA induces 
SASP in HSCs, which in turn promotes HCC development [22-24]. 
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Hepatic stellate cells activation and retinoic acid 
A hallmark of HSCs in their quiescent state in healthy liver is the storage of large 
amounts of vitamin A (or retinol) in the form of lipid droplets of retinyl esters, mostly 
retinyl palmitate [3, 4]. Vitamin A and its metabolites, collectively known as retinoids, 
are essential for normal cell growth and differentiation, for vision, reproduction and for 
the proper functioning of the immune system [3, 4, 25].The source of retinoids is 
represented by animal and plant foods, the latter mainly containing carotenoids to be 
converted into retinoids. Once absorbed by the intestine, retinoids bound to 
chylomicrons enter the circulation and are targeted to liver and other organs and 
tissues, where retinol is converted into retinaldehyde and this, in turn, is oxidized to 
retinoic acid (RA) [26]. RA is the main biologically active form carrying out the majority 
of the aforementioned functions [25, 26], especially in its all-trans and 9-cis isomeric 
forms [3]. Canonically, RA acts by binding to nuclear retinoic acid receptor -α, -β,  or -
γ (RARs) working as heterodimer with retinoid X receptor -α, -β,  or -γ (RXRs) and 
resulting in regulating the expression of hundreds of target genes containing a retinoic 
acid responsive element (RARE) [25, 26]. In addition to this signaling pathway, 
however, RA is known to also bind another kind of nuclear receptor, namely 
peroxisome proliferator-activated receptor beta (PPARβ) and even to exert its effects 
in a non-transcriptional way, by activating kinase cascades rather than gene 
expression [25, 26]. 
The liver is the main organ involved in retinoid storage and metabolism. In particular, 
hepatocytes take up retinoids from the bloodstream, hydrolyze retinyl esters, 
conjugate the hydrophobic retinol with a retinol binding protein (RBP) and transfer the 
complex retinol –RBP to HSCs, in which it is again esterified and stored in lipid 
droplets. HSCs account for the storage of up to 80% of the total body retinol content 
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[3], and are responsible for its release into the bloodstream when the dietary intake 
does not meet the body requirement [4, 27]. Beside storing retinol, HSCs also 
metabolize it and respond to RA since they have been reported to express enzymes 
for retinol to retinaldehyde and retinaldehyde to RA conversion and both RARs and 
RXRs for regulating target genes expression [4]. 
Following liver injury, HSCs undergo a process of activation during which they become 
myofibroblast-shaped, proliferative and fibrogenic. The activation of HSCs is 
accompanied by a marked depletion of retinoid stocks [4, 27], even though the 
meaning of this event is still not fully understood. Whether retinol loss is a cause or a 
secondary effect of HSCs activation or whether administration of retinol/RA could have 
a therapeutic effect in liver disease is not clear [27, 28]. A number of reports would 
suggest a potential use of retinol/RA as anti-fibrotic drug. Studies on cultured cells 
showed retinoids to inhibit HSCs proliferation and activation [29-32]. In vivo studies 
demonstrated that the administration of retinol or its derivatives decreases liver fibrosis 
in different experimental models [33-37]. Beta-carotene, a precursor of retinol, was 
shown to cause a milder pathological phenotype in a rat model of CCl4– induced 
hepatic fibrosis when compared to untreated controls [36]. Consistently, retinol 
administration prevented liver fibrosis induced by CCl4 by suppressing HSCs activation 
[34, 37], and retinyl palmitate treatment in rats injured with dimethylnitrosamine or with 
pig serum decreased the number of activated HSCs thereby preventing collagen 
deposition and fibrosis in liver [33]. The all-trans RA isomer was found to alleviate 
ethanol-induced liver damage [35]. On the other hand, some conflicting papers exist 
reporting a hepato-toxic and pro-fibrotic effect of retinoids [38-40].  
Another controversy concerns the responsiveness of HSCs to retinoids in their 
activated state [41]. As already stated, quiescent HSCs express the nuclear receptors 
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RARs and RXRs through which they modulate gene expression upon RA stimulus [4]. 
The expression of these receptors, on the contrary, was found to be down-regulated 
at the mRNA level and undetectable at the protein level in activated HSCs and not to 
increase upon exogenous RA administration [42, 43], thus suggesting HSCs 
unresponsiveness to RA during activation. Opposing evidence is provided by Mezaki 
et al., who showed the protein expression of the receptors RAR-α and RAR-β to be 
increased in activated rat HSCs, despite lower mRNA levels. Moreover, HSCs were 
found to become responsive to all-trans RA only during activation due to post-
transcriptional up-regulation of RAR-α [41].  
Other lines of evidence support the importance of HSCs and retinol metabolism in liver 
health. RA plays a role in the negative modulation of liver fibrosis through the activation 
of the immune system cells, and namely NK cells. Early activated HSCs express high 
levels of retinoic acid early inducible gene 1 (RAE-1) which binds the NKG2D receptor 
on NK cells resulting in their activation [16]. Activated NK cells, in turn, become 
cytotoxic towards activated HSCs and HSC killing ameliorates fibrosis [4, 16, 44]. 
Finally, the patatin-like phospholipase domain- containing 3 (PNPLA3) has been 
identified as a lipase catalyzing the hydrolysis of retinyl esters in HSCs [45], that would 
account for the retinol stores depletion occurring during cell activation. Interestingly, 
the I148M polimorphism in PNPLA3 gene in HSCs, causing loss of retinyl esterase 
activity, is associated with chronic liver disease and hepatocellular carcinoma [45, 46]. 
 
Retinoic acid and senescence 
As stated above, HSC senescence could represent a mechanism of fibrosis reversal 
[8-10].  
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Retinoids have their clinical application in the therapy of some kinds of hematological 
and solid cancers and in the prevention of pre-neoplastic to neoplastic disease 
progression [47]. The rationale for this use relies on at least three mechanisms of 
action: promotion of differentiation of abnormal cells back to normal, induction of 
apoptosis, block of cell cycle at the G1 stage [48]. As for the cell cycle arrest, all trans 
– RA was found to repress positive G1 regulators and to up-regulate the expression of 
cycle inhibitors, such as p16, p21 and p27 [48]. Since p16 and p21 are involved in the 
process of senescence, Park et al. [48] investigated on whether all trans – RA could 
promote senescence as well. They found it to cause irreversible cell cycle arrest at G1 
phase in the human hepatic cell lines HepG2 and Hep3B, in the human embryonic 
kidney cell line HEK293 and in the human breast cancer cell line MCF-7.This arrest 
was in every case dependent on the up-regulation of p16 and/or p21 [48]. Similarly, 
retinoids were found to induce senescence in T-cell leukemia cells [49]. 
An interesting evidence linking RA with senescence in stellate cells, was obtained by 
Froeling et al. in pancreatic stellate cells (PSCs) [50], a kind of cells located in the 
periacinar, perivascular and periductal regions of the exocrine pancreas, and sharing 
many morphological and functional features with HSCs [51]. As their liver counterpart, 
indeed, PSCs in their quiescent state store retinol-rich lipid droplets, which are 
depleted upon cell activation [52]. Once activated, PSCs acquire a myofibroblast-like 
shape, become motile and proliferative and produce huge amounts of extracellular 
matrix components driving the fibrogenic process [52]. Interestingly, all trans- RA 
administration was shown to restore a quiescent state in PSCs, both in vitro and in 
vivo, thus slowing pancreatic cancer progression [50]. 
Although until now no reports are available about a putative ability of retinoids to 
induce senescence in HSCs,  one might speculate that retinoid treatment could 
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potentially activate the senescence program in these cells too, and this would 
contribute to reverse HSCs activation and thus to reverse liver fibrosis. 
 
 
Retinoic acid and PPAR-gamma signaling 
As discussed above, the canonical signaling of RA is through its receptors RARs and 
RXRs, the latter being prone to form heterodimers with other nuclear receptors, among 
which PPARs [53].  
PPARs are a family of nuclear ligand– activated transcription factors regulating 
metabolism, above all the lipid one, in inflammation, cell growth and differentiation [54-
56]. This family includes three members, namely PPARα, PPARβ/δ and PPARγ, 
differing from each other for tissue distribution, ligand selectivity and biochemical 
properties [54]. The PPARs work as heterodimers with RXRs and they are activated 
upon binding of either natural or synthetic lipidic compounds, which induce structural 
changes making the PPAR-RXR complex able to bind to specific responsive 
sequences on DNA and to allow target gene expression [55, 56]. PPARγ is the most 
studied among PPARs. It exists in two splicing-generated isoforms, PPARγ1 and 
PPARγ2, the former being ubiquitously expressed while the latter nearly restricted to 
adipose tissue [54]. PPARγ is mainly known for its central role in driving adipogenesis 
and lipid metabolism, since it promotes the expression of genes involved in lipid uptake 
and storage [55]. Moreover, PPARγ regulate adipose secretions such as adiponectin, 
leptin, resistin, TNF-α and it takes part in glucose homeostasis and response to insulin 
[54], as it upregulates the glucose transporter 4 (GLUT4) [57]. The latter aspect has a 
considerable importance in the clinical field, where a class of drugs known as 
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thiazolidinediones (TZD), used as insulin sensitizers in the treatment of type 2 
diabetes, have revealed to be PPARγ activators [58-60]. 
Unlike PPARα and PPARβ/δ, PPARγ is poorly expressed in the liver [61], nevertheless 
it is essential for lipid metabolism in this organ. Studies performed in liver-specific 
knock-out mouse models demonstrated that liver ablation of PPARγ impairs 
triglyceride clearance, increases body fat mass [62], decreases the expression of  
genes involved in lipogenesis, lipid transport and β-oxidation and protects from the 
development of hepatic steatosis [62, 63]. Moreover, PPARγ has a protective role 
against liver fibrosis, since in vivo fibrogenesis upon injury turned out to be decreased 
in PPARγ- depleted and enhanced in PPARγ- overexpressing rat livers [64, 65]. This 
modulation of liver fibrosis by PPARγ is likely due to its effect on HSCs, since PPARγ 
agonists or ectopic expression of PPARγ in activated HSCs were shown to inhibit 
proliferation, induce apoptosis and cell cycle arrest, and promote reversal from an 
activated to a quiescent state [66-69]. 
Whether PPARγ effects on HSCs are somehow related to  retinol metabolism in these 
cells is still uncertain, although they share the same trend: as retinol, also PPARγ is 
abundant in quiescent HSCs and dramatically decreases upon activation [69, 70]. 
Furthermore, several analogies subsist between HSCs and adipocytes: both cell types 
store lipid droplets, both undergo a process of differentiation/transdifferentiaton in 
which PPARγ is a master regulator. Both preadipocytes and activated HSCs have a 
fibroblast-like shape, and express the same types of interstitial collagens. Because of 
all these similarities, it is currently believed that these cell types are strongly 
interrelated and maybe regulated by the same master transcription factor, namely 
PPARγ [71, 72]. Some reports support the existence of a combined and synergistic 
action of RA and PPARγ in HSC fate and, thus, in the course of liver fibrosis [73, 74]. 
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Combined treatment with the PPARγ ligand 15-Δ12,13-prostaglandin L(2) and the 
RXR ligands all trans-RA and 9cis-RA on rat primary HSCs led to cell cycle arrest, 
inhibition of lipid droplets release and down-regulation of fibrotic markers such as 
collagen Iα1 and αSMA to an extent which is greater than the effect produced by each 
ligand alone [74]. 
The reciprocal interconnection between PPARγ and retinoids, however, is quite 
controversial. The all trans- RA was found to protect mice from diet-induced hepatic 
steatosis through a cascade culminating in the suppression of the lipogenic PPARγ2: 
all trans- RA binding to RAR activates the repressor hairy and enhancer of split 6 
(Hes6) which, in turn, represses PPARγ2 expression [75]. Moreover, RA and the 
synthetic retinoid fenretinide block the C/EBPα-PPARγ pathway in the adipogenic 
process [76-78] and, accordingly, the RARα antagonist Ro 41-5253 promotes pre-
adipocytes differentiation into mature adipocytes by working as activator of PPARγ 
[79]. 
Discordantly, in myeloid cells retinoids were reported to enhance PPARγ expression 
and activity, which is required for the differentiation of this lineage [80]. This would 
suggest that the cross-talk between retinoids and PPARγ is cell type specific. 
Much less information is available for the inverse relationship between retinoids and 
PPARγ, i.e. whether PPARγ can modulate retinoid metabolism. In human dendritic 
cells PPARγ activation induces the expression of genes responsible for retinol 
metabolism and conversion to all trans- RA, which is at last able to modulate immune 
cell functions [81]. 
In light of all these observations, and based on its expression in the HSCs quiescent 
state and on its repression in activated HSCs, PPARγ has been proposed to potentially 
represent a new molecular target in the reversal of liver fibrosis [70, 71]. 
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Conclusion 
Liver fibrosis is a scarring process taking place as a consequence of chronic damage 
and inflammation of this organ and represents a major clinical challenge since it 
degenerates into cirrhosis with consequent liver failure and poor prognosis. The main 
responsible cells for fibrogenesis are HSCs which, upon liver injury, undergo an 
activation process and begin to produce and deposit extracellular matrix forming scar 
tissue. 
Fibrosis has long been considered an irreversible mechanism but recently it has been 
uncovered that HSCs may undergo a phenotype reversion accounting for fibrosis 
regression [9].  
The hallmark of HSCs is the storage of large amounts of retinol in the form of retinyl 
esters in lipid droplets which are depleted upon cell activation, generating 
metabolically active forms of RA [4, 27]. Concomitantly, PPARγ expression, which is 
substantial in quiescent HSCs, significantly decreases following activation [64, 65]. 
Since RA acts through retinoid receptors which synergize with PPARγ, and since both 
retinoids and PPARγ have proven to be able to reverse HSCs activation and liver 
fibrosis [73, 74], it is tempting to propose that a combined treatment with retinoid 
receptor agonists and PPARγ agonists may potentially represent a new and more 
beneficial strategy in the clinical management of liver fibrosis (Figure 1).  
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Figure 1 
HSCs are able to metabolize retinol to give both retinyl esters (then stored in lipid droplets) and 
retinoic acid. Moreover, HSCs express the nuclear receptors for retinoic acid RARs, which, together 
with RXRs, bind to DNA on Retinoic Acid Responsive Elements (RARE) and modulate target genes 
expression. 
 
 
Table 1: 
Characteristics of the studies showing the anti- or the pro-fibrotic effects of retinoids on liver 
Type of retinoid  Organism/cells   Effect     References 
 
Anti-fibrotic effect of retinoids 
13-cis-retinoic acid   Cultured rat HSCs  Inhibition of proliferation and transformation          Chi et al. [67] 
13-cis-retinoic acid   Rat and cultured rat 
HSCs   Inhibition of activation     Davis et al. [68] 
         
Vitamin A   Cultured rat HSCs    Inhibition of proliferation     Davis et al. [69] 
All-trans retinoic acid  Rat HSC line  Inhibition of proliferation and collagen production   Ye and Dan[71] 
Retynyl palmitate   Rat   Suppression of hepatic fibrosis induced by  
dimethylnitrosamine/pig Serum             Mizobuchi et al 
[72] 
Vitamin A   Rat  Suppression of CCl4-induced HSCs activation and fibrosis                        Noyan et al. 
[73] 
 
All-trans retinoic acid  Rat  Amelioration of ethanol-induced liver injury    Pan et al. [74] 
Beta carotene   Rat  Alleviation of CCl4-induced hepatic inflammation and fibrosis                  Seifert et al. 
[75] 
 
Vitamin A   Rat  Suppression of hepatic fibrosis induced by CCL4/pig serum            Senoo and 
Wake [76] 
All-trans retinoic acid  Mouse  Amelioration of CCl4-induced liver fibrosis            Hisamori et al. 
[77] 
 
Pro-fibrotic effect of retinoids  
9-cis-retinoic acid   Rat  Exacerbation of pig serum-induced liver fibrosis    Okuno et al. 
[79] 
Vitamin A (high levels)  Rat  Exacerbation of CCl4-induced liver fibrosis    Vollmar et al. 
[80] 
Vitamin A   Humans  Dose-dependent chronic liver damage     Geubel et al. 
[78] 
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Figure 2 
Natural or synthetic lipid compounds, such as thiazolidinediones (TZD) are agonists for the 
transcription factor PPARc, which heterodimerizes with RXR, binds to DNA on PPAR responsive 
elements (PPRE) and drives transcription of a number of target genes involved in lipid and glucose 
metabolism, inflammation, cell growth. 
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Figure 3 
Alcohol, toxins, hepatic viruses, autoimmune disorders and other kinds of injuries cause the 
transdifferentiation of hepatic stellate cells (HSCs) from a quiescent to an activated, pro-fibrotic state. 
The combined action of retinoid receptor agonists (such as RA) and PPARc agonists (such as TZDs) may 
synergistically bring activated HSCs back to a quiescent phenotype, accounting for fibrosis reversal. 
